|
|
Article: LUNESTA(TM) Perimenopause-Menopause Study Data to Be Presented at North American Menopause Society Annual Meeting.
- Article from:
- Business Wire
- Article date:
- September 30, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announces the presentation of results from its Phase IIIB/IV study evaluating safety and efficacy of LUNESTA(TM) brand eszopiclone for treatment of insomnia in perimenopausal and menopausal women at the North American Menopause Society's annual meeting in San Diego.
In this six-week, 410-patient, randomized, double-blind, placebo-controlled study, nightly use of LUNESTA 3 mg resulted in statistically significant improvement from baseline compared with placebo in patient-reported measures of sleep latency (time to sleep onset; p
Compared to baseline and averaged over the double-blind period, women treated ...